Samsung Bio & Hanmi will participate at JPM 2021

Held online on January 11-14, Celltrion will be absent after 10 years

Enjikem, Genome & Co, ABL Bio, Crystalgenomics, etc. are also declared to participate

At the 38th JPMorgan Healthcare Conference held this year, Kwon Se-chang, President of Hanmi, announces R&D strategies.

 

This 39th event will be held online under the influence of COVID-19

20 domestic pharmaceutical bio companies announced their participation in the JPMorgan Healthcare Conference, which will be held early next year.

 

Among them, Samsung Biologics was the only one to be assigned a main session presentation.

 

Celltrion, who attended every time, declared absence after 10 years.

 

The JPMorgan Healthcare Conference, which marks its 39th year next year, is the largest conference in the bio field where global pharmaceutical companies share new drug R&D achievements and status, and understand trends in the global pharmaceutical industry.

 

This conference will be held online from January 11th to 14th due to COVID-19.

 

◆Samsung Biologics debuts as new president, John Rim There were about 20 domestic companies that announced their participation in the JPMorgan conference by the 28th.

 

Samsung Biologics is one company that has been assigned the main track.

 

The announcement was scheduled for the morning of the 13th.

 

Although the details of the announcement have not been decided yet, it is attracting attention in that it is the first official stage of the newly appointed John Rim.

 

Hanmi, Hugel, HK inno.N, LG Chem, and Genexine were assigned to announce an auxiliary session (Emerging Market Track).

 

Hanmi is scheduled to announce on the afternoon of the 11th and the rest of the companies on the morning of the 13th.

 

Hanmi has not yet decided on a specific announcement.

 

Last year, they announced HM15211, which is being developed as a treatment for NASH.

 

Hanmi has released three HM15211-related research results in succession this year at the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.

 

The Food and Drug Administration (FDA) has designated this substance as Fast Track.

 

HK inno.N is participating in this event for the first time.

 

HK Innoen plans to introduce autoimmune disease treatment and NASH treatment, including Kcab.

 

Genexine will introduce the business strategy of Continuous Interleukin-7 (GX-17).

 

GX-17 is a substance under development as an anticancer drug for various indications and a treatment for COVID-19.

 

Celltrion, a regular member of JPM conference, decided to absent after 10 years.

 

Celltrion was initially reported to have been assigned to the main track along with Samsung Biologics, but will not attend this event to focus on the development of corona antibody treatment.

 

◆Bio companies such as Enjikem·Genome & Co have also declared participation Enjikem·Genome & Co·ABL Bio·Crystalgenomics· AptaBio·SCM LifeScience Co Ltd·Cellivery·KoBioLabs·Bioleaders·Eoflow are also planning to participate in this JP Morgan conference.

 

Enjikem introduces EC-18, which is being developed as a treatment for COVID-19, and a treatment for oral mucositis caused by chemoradiation on cancer.

 

Phase II clinical trials for oral mucositis are in the final stage.

 

The company plans to announce the results of Phase II in the first half of next year.

 

Genome & Co plans to discuss technology transfer of pipelines such as new immune checkpoint inhibitors and autism treatments.

 

At last year's JP Morgan conference, discussions on additional co-development of GEN-001, a microbiome-based immune anticancer drug, jointly developed with Merck and Pfizer will also be in progress.

 

ABL Bio plans to focus on its dual antibody platform Grabody-B, which increases the penetration rate of the blood-brain barrier, and ABL301, a Parkinson's disease treatment that introduced it.

 

Crystalgenomics will be presenting the data of Ivaltinostat, CG-745', a new drug candidate for anticancer and antifibrosis treatment.

 

AptaBio introduces the company's core platform technology and pipeline, focusing on the diabetic nephropathy treatment APX-115.

 

APX-115 is undergoing multi-national phase II clinical trials in Europe.

 

Patients started medication for the first time in September, and interim data is expected to be available in the first quarter of next year.

 

Cellivery will announce the efficacy and development status of its immunotherapy iCP-NI as a treatment for COVID-19.

 

In addition, it plans to release data on the efficacy of iCP-Parkin, a dementia treatment drug that utilizes TSDT, a drug substance transmission technology in vivo.

 

KoBioLabs shares the clinical progress of major microbiome new drug pipelines, such as KBLP-001 and KBLP-002, the immune disease tasks that are undergoing global clinical trials.

 

In addition, KBLP-004, a microbiome-derived effective substance-based NASH treatment, plans to explore the possibility of joint research and technology transfer from a preclinical study based on the research results on a new target identified by KoBioLabs.

 

Bioleaders introduces research and clinical programs using Huma MAX and MucoMAX technology, which are self-developed new drug platforms.

 

It is also planning to discuss the licensing of anticancer drugs and Sacopenia candidates as well as clinical trials for cervical intraepithelial neoplasia and Duchenne muscular dystrophy treatments.

 

Expectations and concerns coexist in the pharmaceutical industry over this event, which is held online for the first time in 39 years.

 

While there are concerns that the opportunity for business meetings will decrease, there is also an expectation that more active meetings will be possible because there are no temporal and spatial constraints.